期刊
VACCINE
卷 40, 期 30, 页码 4017-4025出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2022.05.046
关键词
SARS-CoV-2; COVID-19 vaccine; Virus-like particle; AS03; Heterologous regimen; Variant of concerns; Cross-neutralization
资金
- Medicago Inc
Since 2019, the global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, leading to coronavirus disease 2019 (COVID-19), has affected hundreds of millions of people. Safe and effective COVID-19 vaccines are now available, but the emergence of variants and the risk of viral escape from vaccine-induced immunity require the development of broadly protective vaccines. A plant-derived virus-like particle vaccine was assessed in mice and shown to induce strong and broadly cross-reactive neutralizing antibody responses against various variants.
Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulting in the coronavirus disease 2019 (COVID-19) has afflicted hundreds of millions of people in a worldwide pandemic. Several safe and effective COVID-19 vaccines are now available. However, the rapid emergence of variants and risk of viral escape from vaccine-induced immunity emphasize the need to develop broadly protective vaccines. A recombinant plant-derived virus-like particle vaccine for the ancestral COVID-19 (CoVLP) recently authorized by Canadian Health Authorities and a modified CoVLP.B1351 targeting the B.1.351 variant (both formulated with the adjuvant AS03) were assessed in homologous and heterologous prime-boost regimen in mice. Both strategies induced strong and broadly cross-reactive neutralizing antibody (NAb) responses against several Variants of Concern (VOCs), including B.1.351/ Beta, B.1.1.7/Alpha, P.1/Gamma, B.1.617.2/Delta and B.1.1.529/Omicron strains. The neutralizing antibody (NAb) response was robust with both primary vaccination strategies and tended to be higher for almost all VOCs following the heterologous prime-boost regimen.(c) 2022 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据